The neurohypophyseal neuropeptides (Arg8)-vasopressin (AVP) and [pGlu4, (where pGlu is pyroglutamic acid and Cyt is cystine) facilitate the retention of one-trial-learning passive avoidance behavior in rats when administered into the cerebral ventricle immediately after the learning trial. The fragment [pGlu4,Cyt'JAVP-(4-8) was considerably more effective than AVP. Oxytocin (OXT) and [pGlu", have the opposite effect and attenuate passive avoidance behavior also when administered into the cerebral ventricle after the learning trial. Again the fragment was more active than the parent molecule. The ancient arginine-containing neurohypophyseal hormone vasotocin in "high" doses (10 ng) had a vasopressin-like effect and in "low" 
[pGlu",Cyt'JOXT- (4) (5) (6) (7) (8) have the opposite effect and attenuate passive avoidance behavior also when administered into the cerebral ventricle after the learning trial. Again the fragment was more active than the parent molecule. The ancient arginine-containing neurohypophyseal hormone vasotocin in "high" doses (10 ng) had a vasopressin-like effect and in "low" doses (0.1 ng) had an OXT-like effect on passive avoidance behavior. Because both vasopressinergic (Vj) and oxytocinergic receptors have been demonstrated in the central nervous system, we asked whether specific antagonists of the V1, V2, and OXT receptor could antagonize the effects of these neuropeptides on passive avoidance behavior. The three antagonists were approximately equally active in blocking the effect of vasopressin, whereas the fragment [pGlueJAVP- (4) (5) (6) (7) (8) and the high dose of vasotocin were more readily blocked by the OXT antagonist. The attenuating effect of OXT, the fragment [pGluCytJOlXT- (4) (5) (6) (7) (8) , and the low dose of vasotocin was markedly reduced by the OXT antagonist. This effect could also be reduced by pretreatment with the V1 antagonist but not with the V2 antagonist. These results suggest the existence of a separate neurohypophyseal hormone receptor complex in the brain affecting memory processes that differs from the peripheral V1, V2, and OXT receptor.
Numerous reports suggest profound effects of exogenously administered (1, 2) and centrally released (for review, see ref.
3) neurohypophyseal neuropeptides on processing of newly acquired information. Recently, vasopressinergic (4-6) and oxytocinergic (6-8) binding sites have been described in the central nervous system. Evidence has accumulated that the larger part of specific vasopressinergic binding sites in the limbic system-the brain areas mediating the action of neurohypophyseal neuropeptides on learning/memory processes-have a ligand specificity that resembles that of peripheral vasopressinergic receptors of the V1 type. In agreement with this suggestion is the behavioral observation (9, 10) (11) . The V1 vasopressinergic antagonist was also effective in preventing the action of [pGlu4,Cyt6]AVP-(4-8) (where pGlu is pyroglutamic acid and Cyt is cystine), a more selective behaviorally active putative endogenous metabolite of AVP (12) . Because [pGlu4,CytI]AVP-(4-8) had no effect on blood pressure, diuresis, and body temperature, these data indicated that the receptors involved in the action of AVP on behavior are clearly separated from those involved in the pressor response (11, 13) .
More recent data, however, raised the possibility that the involvement of various neurohypophyseal neuropeptidereceptor types might be more complex than originally suggested. Accordingly, V2-type vasopressinergic receptors have been suggested to be present in the brain (14) . More Table 1 .
Histological Control. Localization of the cannula tip was determined at the end of the experiment by injection of Evans blue.
Statistical Analysis. Differences in passive avoidance latencies were analyzed by the Mann-Whitney nonparametric ranking test. Table 2 summarizes the effects of graded doses of the receptor antagonist when injected alone. Neither AAVP(V1), AAVP(V2), nor AOXT in the doses used significantly affected the retention ofpassive avoidance behavior. The effect of postlearning AVP treatment and the interaction of AVP with various doses of the receptor antagonists is also summarized in Table 2 . Statistical analysis revealed significant differences in the 24-hr and 48-hr avoidance latencies among the various treatment groups. AVP in a dose of 1 ng very significantly facilitated retention ofpassive avoidance behavior at both 24-and 48-hr retention sessions. Pretreatment with To determine the attenuating effect of OXT-like neuropeptides, a higher shock intensity was used. Thus, avoidance latencies were much higher than in previous experiments. AAVP-V2 (20) (21) (22) 6.42 8.04 6.90
RESULTS
*Antagonistic potencies are expressed in pA2 values. pA2 is the negative log of A2, which is the concentration of antagonist needed to reduce the response to two times the amount of agonist to equal the response to one time the amount administered before the antagonist.
tRelative binding affinities are given in pK1 values. pK, is the negative log of the inhibition constant calculated from the IC50 value (23). duced passive avoidance behavior in doses of 3 and 10 pg. This effect was blocked by the 1-ng dose but only partly by the 0.3-ng dose of the antagonist.
In accordance with previous data [pGlu4,Cyt6]AVP-(4-8) is more potent in facilitating passive avoidance behavior than AVP itself (12) . Accordingly [pGlu4,Cyt6]AVP-(4-8) already facilitated passive avoidance behavior in a dose of 10 pg (Table 4) although the lowest dose of the neuropeptide was not significantly reduced (Table 5) .
AOXT at 1 ng per rat significantly blocked the effect of [pGlu4,Cyt6]AVP-(4-8) in all three doses investigated (Table  5) . AOXT therefore appeared more potent than the V1 and V2 antagonists in blocking the effect of the AVP fragment. A lower dose of AOXT (0.3 ng) significantly blocked the effect of the 3-and 10-pg doses of the fragment, but the lowest dose of 0.1 ng was less effective (Table 6 ).
Subsequently the influence of the three antagonists was measured on the effect of OXT. Again, the higher shock intensity of 0.5 mA for 2 sec was used. Because 1 ng of the antagonists markedly affected passive avoidance behavior (data not shown), the 0.3-ng dose was used, which also had a blocking effect on AVP-induced facilitation of passive avoidance behavior (see Table 3 ). Table 6 summarizes the results. OXT at 1 ng significantly attenuated passive avoidance responses. This attenuation was significantly blocked by 0.3 ng of AAVP(V1) and the same amount of AOXT but not by AAVP(V2). Both AAVP(V1) and AOXT as such reduced passive avoidance responses, although not significantly.
In a final series of experiments, the influence ofthe ancient neurohypophyseal hormone vasotocin ([Arg8]OXT) was studied. This neuropeptide in "high" doses has a vasopressin-like and in "low" doses has an OXT-like effect on passive avoidance behavior as shown in Fig. 1 . The effect of 10 ng ofvasotocin was significantly blocked by AOXT at 1 ng, whereas all three antagonists significantly blocked the effect of this neuropeptide at 3 ng (Table 7) . To study the attenuating effect of vasotocin on passive avoidance behavior a dose of 0.1 ng was used, and the influence of 0.3 ng of the three antagonists was determined as in the study with OXT ( Table 8 ). Only the AAVP(V1) and AOXT blocked the effect of vasotocin. Vasotocin-induced attenuation of passive avoidance behavior was not significantly affected by pretreatment with AAVP(V2).
DISCUSSION
These results confirm our previous findings (11) hypophyseal hormones, vasotocin, has a bimodal effect. In high doses it mimics vasopressin, and in low doses it mimics OXT. The effect of the high as well as the low dose was blocked by AAVP(V1) and AOXT; AAVP(V2) was less effective.
The use of antagonists for experiments such as those described in this paper may be questioned when one considers the specificity of these compounds from the data listed in Table 1 . This seriously handicaps determination of the receptor involved. We tried to solve this problem by using graded doses of the three antagonists to titrate their relative potency. From these studies we conclude that the three antagonists were almost equally effective in blocking the what lesser affinity for AAVP(V2). Such a receptor might be present in the ventral hippocampus. Here we hypothesize that the receptor implicated in these behavioral effects could well be the so-called OXT receptor.
Binding data have shown that AVP can also bind to OXT receptors (6, 8) . The locus of action of neurohypophyseal hormones and related neuropeptides is in the septal hippocampal area-in particular, the ventral subiculum (18) . This region mainly contains OXT-binding sites (8) Earlier studies showed that the ventral hippocampus, the amygdala, and the septal area were the most effective regions for the effect of neuropeptides related to the neurohypophyseal hormones on passive avoidance behavior (24) . These regions and especially the ventral hippocampus are known to express both OXT and AVP receptors. Furthermore, OXT, but also vasotocin and AVP, have equally high affinities for this so-called OXT receptor, whereas OXT has a lower affinity for the peripheral and central AVP receptors. Moreover, the OXT analogue that appears to be a powerful antagonist of the neurohypophyseal peptides on the passive avoidance behavior test has a very low affinity for the AVP receptor and a low antagonistic potency in the vasopressor and antidiuretic assay, whereas it has a high affinity for the hippocampal OXT receptor and a high antagonistic potency in the uterus-contraction assay. Binding studies with brain homogenates indicated that AOXT is very selective for OXT receptors, both in brain and in peripheral tissue. OXT and related peptides have effects opposite those of vasopressin and related peptides (25) . These amnesic peptides attenuate active and passive avoidance behavior. Indeed, administered i.c.v., OXT also dose-dependently attenuated passive avoidance behavior in the present experiments. This effect was readily blocked by AOXT. AAVP(V1) but not AAVP(V2) also blocked the behavioral effect of OXT. Thus, the same antagonists that block the behavioral effect of vasopressin neuropeptides also block the behavioral effect of OXT neuropeptides. This result suggests that the same receptor complex is used for the two classes of memory-modulating ligands.
We propose here a neurohypophyseal hormone receptor complex in which vasopressin and its analogues act as agonists and in which OXT and related compounds may act as "inverse" agonists. Both the agonistic and "inverse" agonistic actions can be blocked by AOXT. This concept seems useful as a functional model. However, no direct molecular proof exists for such a putative receptor complex. 
